These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 9851727)

  • 1. Intravenous immunoglobulins in multiple sclerosis.
    Lisak RP
    Neurology; 1998 Dec; 51(6 Suppl 5):S25-9. PubMed ID: 9851727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of intravenous immunoglobulin in the treatment of multiple sclerosis.
    Sorensen PS
    J Neurol Sci; 2003 Feb; 206(2):123-30. PubMed ID: 12559498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group.
    Fazekas F; Deisenhammer F; Strasser-Fuchs S; Nahler G; Mamoli B
    Lancet; 1997 Mar; 349(9052):589-93. PubMed ID: 9057729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous immunoglobulins as therapeutic option in the treatment of multiple sclerosis.
    Dudesek A; Zettl UK
    J Neurol; 2006 Sep; 253 Suppl 5():V50-8. PubMed ID: 16998754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis.
    Sorensen PS; Wanscher B; Jensen CV; Schreiber K; Blinkenberg M; Ravnborg M; Kirsmeier H; Larsen VA; Lee ML
    Neurology; 1998 May; 50(5):1273-81. PubMed ID: 9595974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of multiple sclerosis with intravenous immunoglobulin: review of clinical trials.
    Sørensen PS
    Neurol Sci; 2003 Oct; 24 Suppl 4():S227-30. PubMed ID: 14598048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis.
    Sorensen PS; Fazekas F; Lee M
    Eur J Neurol; 2002 Nov; 9(6):557-63. PubMed ID: 12453069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind, cross-over trial of intravenous immunoglobulin G in multiple sclerosis: preliminary results.
    Sørensen PS; Wanscher B; Schreiber K; Blinkenberg M; Jensen CV; Ravnborg M
    Mult Scler; 1997 Apr; 3(2):145-8. PubMed ID: 9291170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses.
    Achiron A; Gabbay U; Gilad R; Hassin-Baer S; Barak Y; Gornish M; Elizur A; Goldhammer Y; Sarova-Pinhas I
    Neurology; 1998 Feb; 50(2):398-402. PubMed ID: 9484361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous immunoglobulin in MS: promise or failure?
    Fazekas F; Strasser-Fuchs S; Hommes OR
    J Neurol Sci; 2007 Aug; 259(1-2):61-6. PubMed ID: 17449063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial.
    Hommes OR; Sørensen PS; Fazekas F; Enriquez MM; Koelmel HW; Fernandez O; Pozzilli C; O'Connor P
    Lancet; 2004 Sep 25-Oct 1; 364(9440):1149-56. PubMed ID: 15451222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous polyclonal human immunoglobulins in multiple sclerosis.
    Soelberg Sorensen P
    Neurodegener Dis; 2008; 5(1):8-15. PubMed ID: 18075269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment.
    Lewańska M; Siger-Zajdel M; Selmaj K
    Eur J Neurol; 2002 Nov; 9(6):565-72. PubMed ID: 12453070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Intravenous immunoglobulins (IVIg) in the treatment of multiple sclerosis].
    Achiron A; Miron S
    Ann Med Interne (Paris); 2000 May; 151 Suppl 1():1S41-4. PubMed ID: 10896988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment effects of monthly intravenous immunoglobulin on patients with relapsing-remitting multiple sclerosis: further analyses of the Austrian Immunoglobulin in MS study.
    Fazekas F; Deisenhammer F; Strasser-Fuchs S; Nahler G; Mamoli B
    Mult Scler; 1997 Apr; 3(2):137-41. PubMed ID: 9291168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Intravenous immunoglobulin in multiple sclerosis].
    Ota K
    Nihon Rinsho; 2003 Aug; 61(8):1374-80. PubMed ID: 12962026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous immune globulin in multiple sclerosis: clinical and neuroradiological results and implications for possible mechanisms of action.
    Achiron A; Barak Y; Goren M; Gabbay U; Miron S; Rotstein Z; Noy S; Sarova-Pinhas I
    Clin Exp Immunol; 1996 May; 104 Suppl 1():67-70. PubMed ID: 8625547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.
    Fazekas F; Lublin FD; Li D; Freedman MS; Hartung HP; Rieckmann P; Sørensen PS; Maas-Enriquez M; Sommerauer B; Hanna K; ;
    Neurology; 2008 Jul; 71(4):265-71. PubMed ID: 18645164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.